Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
NCT06458127 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2026-04-06
Summary
This research study is evaluating the feasibility and acceptability of implementing a telehealth palliative care intervention in patients with moderate to severe chronic graft-versus-host disease.
Conditions
- Chronic Graft-versus-host Disease
- Chronic GVHD
- cGVHD
Interventions
- OTHER
-
Tele-palliative care visit
Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
Sponsors & Collaborators
-
Massachusetts General Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-09
- Primary Completion
- 2026-12-30
- Completion
- 2027-12-30
Countries
- United States
Study Locations
More Related Trials
-
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
NCT03128359 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
NCT00608517 ·Status: TERMINATED ·Phase: NA
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
NCT03970096 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00005092 ·Status: COMPLETED ·Phase: PHASE1
-
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
NCT00912223 ·Status: COMPLETED ·Phase: PHASE2
-
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
NCT01858740 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
NCT01487577 ·Status: COMPLETED ·Phase: PHASE2
-
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
NCT02220985 ·Status: COMPLETED ·Phase: PHASE2
-
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT06859424 ·Status: RECRUITING ·Phase: PHASE2
-
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
NCT00001830 ·Status: COMPLETED ·Phase: PHASE1
-
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879 ·Status: TERMINATED ·Phase: PHASE2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT03779854 ·Status: RECRUITING ·Phase: PHASE2
-
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
NCT05515029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
NCT02593123 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
NCT00290641 ·Status: COMPLETED ·Phase: NA
-
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
NCT01177371 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00105001 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
NCT01789255 ·Status: COMPLETED ·Phase: PHASE2
-
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
NCT00611351 ·Status: COMPLETED ·Phase: PHASE2
-
In-Vivo Activated T-Cell Depletion to Prevent GVHD
NCT00594308 ·Status: TERMINATED ·Phase: NA
-
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
NCT00003572 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice
NCT04454723 ·Status: COMPLETED ·Phase: NA
-
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
NCT01233921 ·Status: COMPLETED ·Phase: NA
-
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
NCT02145403 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
NCT02991898 ·Status: TERMINATED ·Phase: PHASE2